TOPLINE: Overall, patients with solid tumors who receive an investigational cancer drug experience small progression-free survival (PFS) and overall survival benefits but much higher toxicity than those who receive a control intervention. METHODOLOGY: The view that patients with cancer benefit from access to investigational drugs in the clinical trial setting is widely held but does …
